The recently launched UK-based MANIFEST collaboration of academic, industry, and National Health Service groups will attempt to understand why less than half of patients respond to immunotherapy, research that could allow clinicians to predict whether a patient is likely to benefit from an immune … The FDA approved zanidatamab (Ziihera; Jazz Pharmaceuticals) for previously treated, inoperable, or metastatic HER2- positive biliary tract cancer (BTC), which targets two distinct HER2 epitopes and is the

Summary:. The conventional wisdom is that the overwhelming majority of neoantigens arise from chromosomal DNA mutations; however, recent studies show that posttranscriptional and posttranslational events can also generate neoantigens. This commentary provides an overview of known and potential sources of nonchromosomal neoantigens, emerging technologies, and clinical trials that may move this field forward to redefine immunologically “hot/cold” tumors and develop next-generation immunotherapeutic approaches.

Summary:. The conventional wisdom is that the overwhelming majority of neoantigens arise from chromosomal DNA mutations; however, recent studies show that posttranscriptional and posttranslational events can also generate neoantigens. This commentary provides an overview of known and potential sources of nonchromosomal neoantigens, emerging technologies, and clinical trials that may move this field forward to redefine immunologically “hot/cold” tumors and develop next-generation immunotherapeutic approaches.